Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Chemotherapy-induced Peripheral Neuropathy 1

Interventions

Metformin 2rosiglitazone-metformin combination 1mirabegron 1lorcaserin 1exemestane 1atezolizumab 1angiotensin I (1-7) 1Traumeel S 1Tirzepatide 1TIC10 compound 1Sodium Chloride 1Rosiglitazone 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Melphalan 1Leflunomide 1Hydroquinones 1Fish Oils 1Fibroblast Growth Factor 7 1Drug Therapy 1Docosahexaenoic Acids 1Cisplatin 1Cholestyramine Resin 1CBLB502 1Ascorbic Acid 1Acupuncture Therapy 1ART123 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × ART123 × Other × Clear all
NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡